Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 2
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P039 - Clinical Characteristics and Survival of Patients with Lymphoepithelioma-Like Carcinoma in Lung and Bronchus and Other Sites (ID 159)
00:00 - 00:00 | Author(s): Y. Liu
Lymphoepithelioma-like carcinoma (LELC), an unusual histological type of malignancy, occurs in almost all anatomic sites of body including lung and bronchus. Although with strong ties to Epstein-Barr virus infection, LELC at different sites has distinct clinical characteristics. Because of the rarity, it is however largely unclear whether LELC at different sites would lead to different prognosis, independent of clinical characteristics.
Based on the population-based cancer cohort from the Surveillance, Epidemiology, and End Results database (SEER), we identified all LELC patients from year 1973 to 2015. According to tumor sites, we classified LELC patients into lung and bronchus, nasopharynx, and another eight most common sites. We studied overall survival as the primary outcome, while tumor characteristics as the secondary outcome.
In total, we identified 2079 LELC patients, of which 86 (4%) were positioned at lung and bronchus and 1208 (58%) at nasopharynx (Figure 1A). Patients with lung and bronchus LELC were older at diagnosis and with more advanced stage, as compared to nasopharyngeal LELC. The 5-year overall survival rates of LELC of lung and bronchus as well as nasopharynx were 35.8% and 59.5% in patients with localized stage (Figure 1B), while 35.1% and 55.5% in patients with regional stage (Figure 1C), respectively. After controlling for tumor characteristics and treatment modes, patients with lung and bronchus LELC were associated with increased risk of overall mortality as compared with LELC of nasopharynx (HR 1.72, 95% CI 1.03 to 2.88).
The demographics and clinical features of LELC greatly differ by organ of origin. Site may be an important predictor for survival in patients of LELC. Compared with LELC of nasopharynx, pulmonary LELC is associated with worse prognosis, independent of common prognostic factors.
P100 - Stem Cell Factor Leads to Lung Cancer Escapes from Anti-Angiogenic Therapy by Increasing the ALDH1+ Lung Cancer Cell Number (ID 146)
00:00 - 00:00 | Author(s): Y. Liu
Although the anti-angiogenic therapy becomes an important treatment for non-small-cell lung cancer, cancer cells can escape from this therapy through several different ways so as to keep growth. Our previous results showed that anti-angiogenic drugs increased the number of ALDH1+ lung cancer cells in mouse models. This study is to explore the significance and mechanism of this phenomenon.
The xenograft tumor murine models and molecular experiments in vitro were used in this study.
In our experiments with murine lung cancer xenografts, we found that the anti-angiogenic agent endostatin increased the number of ALDH1+ lung caner cells. In vitro results showed that SOX and OCT4 were highly expressed in ALDH1+ lung cancer cells. These cells had stronger ability in surviving in hypoxic environment, metastasis and invasion than ALDH1- lung cancer cells. We also found that the expressions of HIF-1a and stem cell factor (SCF) in the xenografts were increased after anti-angiogenic therapy. HIF-1? could up-regulate the expression of SCF in lung cancer cells. The over-expression of SCF can increase the proportion of ALDH1+ cells in lung cancer. The mechanism was related to the HIF-1?/SCF/c-Kit/PI3K/AKT pathway. Finally, when we combined anti-angiogenic therapy with decreasing SCF expression, it is found that the survival time of mice in the combination group was significantly longer than that in the single anti-angiogenic group.
Anti-angiogenic therapy aggravated hypoxia which could induce the up-regulated expression of SCF in lung cancer. SCF promoted lung cancer to escape from anti-angiogenic therapy by increasing the number of ALDH1+ lung cancer cells.